Orchard Therapeutics’ gene therapies will have a new home as Japan’s Kyowa Kirin buys out the biotech for $387.4 million in cash. Kyowa Kirin will now take over marketing of Orchard’s only product, Libmeldy (atidarsagene autotemcel or OTL-200), for a rare and fatal metabolic…
#fda #unlock
Continue reading...